Loading…
Loading…
ISPC does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ISPC and 80,000+ other tickers.
See exactly how ISPC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ISPC and 80,000+ other tickers.
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that…
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international
Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.
WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company's common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.
Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025 Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F.